Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GVHD Prophylaxis with TMS vs AC in Reduced-Intensity Allogeneic HSCT
NCT00520130Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Oct 2007
- Primary completion
- Oct 2015
- Modality
- Nanoparticles, Monoclonal Antibodies, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of alemtuzumab, cyclosporine, tacrolimus + Wuzhi capsule, methotrexate, nab-sirolimus in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS), chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL), sponsored by National Cancer Institute. Started Oct 2007; status: completed.
02
Drugs
alemtuzumabcyclosporinetacrolimus + Wuzhi capsulemethotrexatenab-sirolimus
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)myelodysplastic syndrome (MDS)chronic lymphocytic leukemia (CLL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT00520130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00520130.